Biosimilar Blog

FDA Roundup

• Today, the FDA issued draft Guidance for Industry #278, Human User Safety in New and Abbreviated New Animal Drug Applications, to clarify the current approaches and the FDA’s recommendations for Human User Safety (HUS) assessment and submission

Biosimilars Drug Market is poised to grow a Robust CAGR of +14% by 2030 

A biosimilar (also known as follow-on biologic or subsequent entry biologic) is a biologic medical product that is almost an identical copy of an original product

Lannett Developing Biosimilar Insulin Glargine with HEC Group Set to Launch in 2024

As of April 4, 2023, Lannett Company, Inc. is currently in the process of developing a biosimilar insulin glargine product in partnership with the HEC Group of

Biosimilar Market to Surpass USD 343,520.90 Million by 2029 at a CAGR of 32.00% 

The comprehensive Biosimilar Market business report is a thorough investigation of current scenario of the global market, which covers several market dynamics. Moreover, for the businesses,

The World’s Second Approved Biosimilars of Denosumab (MAILISHU)

biopharmaceutical company with the layout of whole industry chain, announced that the Denosumab solution for injection (trade name: MAILISHU, project code: 9MW0311), which is developed by its wholly-owned subsidiary T-mab, has been